• LINHARDT acquires three production lines for aluminum tubes production from Nussbaum

    News: 

    We are very pleased to inform you that LINHARDT GmbH & Co. KG has acquired all three aluminum tube production lines as well as the customer base and order volume from Nussbaum Matzingen AG under an Asset Purchase Agreement (APA) effective October 31, 2021.
     
    By the end of 2021, LINHARDT and Nussbaum will hold discussions with all customers with the aim of ensuring a smooth transition of orders.
     
    Nussbaum will continue to produce at its Kesswill site until the end of Q1/ 2022 at the latest, so that the dismantling of the production lines will be carried out by LINHARDT at the beginning of Q2/ 2022. Production on these lines at LINHARDT's German sites in Viechtach and Pausa is expected to commence from Q4/2022, following corresponding supplementary investments to be made, although LINHARDT can also produce at its existing production facilities at an earlier desired date.
     
    With this acquisition, says LINHARDT CEO Johannes Schick, "LINHARDT will significantly strengthen its market position in the Pharmaceutical Alumiunium Tubes business unit."
     
    With this sale to LINHARDT, we are convinced that our customers will be in very good hands in the future, so that a smooth and high-quality supply will be ensured, according to the owner and CEO of Nussbaum, Florian J. Nussbaum.

  • Neopac Wins European Tube Manufacturers Association Awards in Laminates, Prototypes Categories

    Company’s Stylo™ Pipette Tube for Filorga takes ‘Laminates’ category; new mono-material barrier tube, Polyfoil® MMB, named best Prototype.

    Oberdiessbach, Switzerland – Hoffmann Neopac, a global provider of high-quality packaging for pharma, beauty and oral care, has won two awards from the European Tube Manufacturers Association (ETMA). One accolade recognized a current customer application, the other a groundbreaking sustainability solution on the verge of market launch.

  • Stevanato Group to showcase the benefits of an integrated solutions approach at CPhI Worldwide Conference, November 9-11

    Spotlight on the development of proprietary devices like the SG Alina pen injector platform

    Piombino Dese (PD), Italy, November 4, 2021 – Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will showcase the benefits of its integrated solutions approach at CPhI Worldwide, November 9-11, 2021. The company will be exhibiting at Fiera Milano in Milan – in the InnoPack zone in Hall 6, Booth #G20.

  • GLOBAL PLASTIC PACKAGING MANUFACTURER SELECTS KANSAS CITY FOR NEW FACILITY

    The ALPLA Group, a global packaging solutions manufacturer and recycling specialist headquartered in Hard, Austria, announced that it has selected the Kansas City region for its new 23,000-square-metre manufacturing plant.

     

    In its new manufacturing plant in Kansas City, ALPLA will produce injection-moulded products such as closures.

    In a facility located at the Blue River Commerce Center in Kansas City, Missouri, the regional organisation ALPLA Inc. will create 75 jobs while continuing to invest in the city over the next several years.

  • Covid vaccine glass tubing maker SCHOTT invest 70 mn euro in Gujarat plant

    News: 

    Leading German specialty glass maker SCHOTT Glass India has announced an additional investment of 70 million euros to expand its Gujarat tubing plant that already makes FIOLAX glass used in Covid-19 vaccine packaging in India.

    According to the company, almost 95 per cent of Covid-19 vaccines in India are packed in glass tubing made by SCHOTT at its plant in Jambusar, Gujarat. In the wake of German Ambassador to India Walter J Lindner's visit to the plant, SCHOTT Glass India's Managing Director Pawan Shukla reiterated the announcement of an additional investment of 70 million euros in the plant, following several million in investments over the last few years.

    "It (the German Ambassador's visit) gave us an opportunity to showcase a successful example of know-how and transfer of technology (TOT) from Germany to India. We have recently announced an investment of 70 million euro in the site to set up additional glass melting tanks and ensure adequate supply to the Indian pharma industry as well as neighbouring countries," said Shukla

    The tubing plant in Gujarat is the Asian manufacturing hub of high-quality pharma glass tubing. It has also been a frontrunner in the fight against Covid-19 and provided pharmaceutical glass for primary packaging to fill billions of Covid-19 vaccines worldwide. In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT, which has been the gold standard for pharmaceutical packaging for more than a century.

    According to SCHOTT, the material is best suited for vaccines and life-saving medications, as it avoids the interactions between containers and the drug formulation that can limit its effectiveness.

    Post his visit, German Ambassador to India Walter J. Lindner said that any vaccination program across the globe would’ve been very difficult without SCHOTT glass.

    "In fact not many people know that SCHOTT glass is responsible for almost 95 per cent of Covid-19 vaccine packaging in India. I want to congratulate the SCHOTT team here as they promote a product that is German high quality and produced in India," he added.

    Earlier this year in August, Serum Institute of India (SII), the world's largest vaccine producer and manufacturer of highly effective biologics, has bought the 50% stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry. The joint venture is the leading Indian manufacturer of pharma packaging products such as vials, syringes, ampoules, and cartridges used to package life-saving medications.

  • SCHOTT glass responsible for almost 95 pc of COVID-19 vaccine packaging in India: German envoy

    News: 

    Jambusar (Gujarat) [India], October 27 (ANI): German Ambassador to India, Walter J Lindner, visited the SCHOTT factory site in Jambusar, Gujarat, on Wednesday and said that the glass manufactured by the company is responsible for almost 95 per cent of COVID-19 vaccine packaging in India.

    The visit is a part of the German Ambassador's two-day trip to Gujarat in which he is visiting important sites. He also interacted with the Indo-German business community. The Ambassador undertook a tour of the factory, talked to employees and learnt about core aspects of pharmaceutical glass production.

    SCHOTT Glass India is part of the technology group SCHOTT with headquarters in Mainz, Germany. According to a SCHOTT release, the company has a long history of producing specialty glass for more than 130 years and "is a global leader in pharmaceutical glass manufacturing".

    "SCHOTT Jambusar is a state-of-the-art facility that produces the best specialty pharma glass in the world, specially the glass used for COVID vaccines," the Ambassador said on his visit.

    "Any vaccination programme across the globe would've been very difficult without SCHOTT glass. In fact not many people know that SCHOTT glass is responsible for almost 95 per cent of COVID-19 vaccine packaging in India. I want to congratulate the SCHOTT team here as they promote a product that is German high quality and produced in India. This is a perfect example of 'Make in India' and 'Industry 4.0'. I am proud Germany is a vital part of this partnership," he added. The release said that the tubing plant in Gujarat is the Asian manufacturing hub of high-quality pharma glass tubing. "It has also been a frontrunner in the fight against COVID-19 and provided pharmaceutical glass for primary packaging to fill billions of COVID-19 vaccines worldwide. In India, almost all approved vaccines are packed in FIOLAX® glass made by SCHOTT, which has been the gold standard for pharmaceutical packaging for more than a century. The material is best suited for vaccines and life-saving medications, as it avoids the interactions between containers and the drug formulation that can limit its effectiveness," the release said. Pawan Shukla, Managing Director SCHOTT Glass India, said they were delighted to have the German Ambassador visit the premises. "It gave us an opportunity to showcase a successful example of know-how and TOT (Transfer of Technology) from Germany to India," he said. Commenting on SCHOTT's future expansion plans, he said, "We have recently announced an investment of 70 million Euros in the site to set up additional glass melting tanks and ensure adequate supply to the Indian pharma industry as well as neighbouring countries," he said. The release said that the expansion in SCHOTT's Jambusar is set to create more than 225 new jobs.

    "It is part of SCHOTT's commitment to invest over 100 million Euros in its Indian tubing facilities and triple the production capacity to produce FIOLAX® glass tubing for domestic and export demands," the release said.

    "Since August this year, SCHOTT also has a new Indian partner: Serum Institute of India, the world's largest vaccine producer and manufacturer of highly effective biologics, has bought the 50% stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry," it added.

    The joint venture is the leading Indian manufacturer of pharma packaging products such as vials, syringes, ampoules, and cartridges used to package life-saving medications, the release said. (ANI)

  • Nemera launches UniSpray, its unidose system primarily for systemic-acting drug administration.

    Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could offer, Nemera is thrilled to extend its portfolio by launching its unidose system, UniSpray, for systemic-acting drug administration to face emergency and crisis.

  • Global Pharma & Drug Delivery Summit

    The Global Pharma & Drug Delivery Summit 2022 would like to welcome all the pharmaceutical professionals and companies, students, researchers, scientists, practitioners, medical specialists, clinical scientists, technologists, and other healthcare professionals to participate and speak at our prestigious Pharmaceutical Summit 2022 slated on August 22-24, 2022 in Frankfurt, Germany.

    This Pharma Summit 2022 revolves around the theme – “Together with Pharma Masterminds: Opportunities, Technology, and Challenges”. The Pharma Summit 2022 will help the delegates to establish their research or business relations as well as to make international linkage for future collaborations in their career path. Your presence will be much appreciated.

    This global meeting is a one-of-a-kind event, where you will have a chance to discuss, access to key benefits of the upcoming sustainable and highly innovative sectors in pharmaceutical R&D. It is one of the largest pharmaceutical conferences in the industry, has a lot to offer you. There would be several sessions at Pharma Summit 2022; right from Opinion makes Discussions, exhibition, networking with peers, to high-end conferences, luncheons, creating it exceptionally worthwhile. 

    Objectives of Pharma Summit 2022

    • To provide attendees with an in-depth knowledge of the novel drug system and formulation research technique being employed by scientists, chemists, and pharmacologists worldwide;
    • To enhance participants with an understanding of where the pharmaceutical sciences and drug development sectors are heading over the next decade, so that they may line-up their career objectives, accordingly in order to raise themselves exceptionally;
    • To spread the enlightenment of drugs and vaccines (for both old diseases and new ones) amongst healthcare professionals, scientists, surgeons, doctors, pharmacists, nurses, and physicians;
    • To promote awareness on development efficacy and ethics to Board Members, Managing Directors, CFOs, CEOs, and other top executives from various pharma and drug-producing industries spread all over the Globe;
    • To encourage research funding and the flow of reproving financial support to scientific projects and travel the world over, that is on the edge of making major advancement that will have crucial importance on the way medical science is dispensed the world over;
    • To provide medical practitioners, and physicians with the latest guidelines on how to go about diagnosing infections and diseases (that scientists have made more discoveries about over the past few years), as well as the refurbished specifications for prescribing the most appropriate course of medication for patients of their illnesses;
    • To boost and promote pharmacology and pharmaceutical science research professionals to wander into the study of new viruses, bacterial infections, diseases, autoimmune disorders, cerebral conditions, etc, and not to stick to the field that already has a considerable number of research projects;
    • To highlight on novel drug system, testing, and deployment techniques that will make easiest and quicker for pharma companies to discover, test, and market their new products more proficiently.

     

     

    For more deatils Click here

    How to get there

    Frankfurt, Germany

    Mainhaus Stadthotel Frankfurt
    Lange Strasse 26
    60311 Frankfurt am Main

     

    Tickets info

    Name: Scarlet Grand

    Phone: +1 256 240 0136

    Email: contactus@worldpharmasummit.com

  • Schütz acquires well established manufacturer of jerrycans and drums

    With the acquisition of GEM Plastics Limited, Schütz is expanding its product portfolio in the field of industrial packaging and further increasing its performance for customers in Ireland and the United Kingdom.

  • Aptar Pharma Enters into Partnership with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

     Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced an exclusive partnership with Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), for the development of a new connected drug delivery device and companion mobile app, the first of its kind, for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.

  • Pages